BioWorld

Jan. 13, 2005

View Archived Issues

Genzyme's 2004: Strong Sales, Growth Provided 'Stellar' Year

With increased revenues of 23 percent in the fourth quarter, Genzyme Corp. exceeded analyst expectations, ending the year with two major acquisitions under its belt and an FDA approval for Clolar. (BioWorld Today) Read More

Sepracor CEO Vows Company Will Become 'Household Word'

Read More

Myriad Moving Flurizan Into Phase III Alzheimer's Testing

Read More

Chelsea Therapeutics' First Round: $14.5M For Antifolate Drug Studies

Read More

Other News To Note

Read More